Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 472,230
  • Shares Outstanding, K 143,317
  • Annual Sales, $ 335,000 K
  • Annual Income, $ -279,660 K
  • 60-Month Beta 1.66
  • Price/Sales 1.53
  • Price/Cash Flow N/A
  • Price/Book 1.26
Trade AKBA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.23
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.31
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +40.17%
on 09/24/20
3.96 -17.17%
on 10/19/20
+0.49 (+17.56%)
since 09/22/20
3-Month
2.34 +40.17%
on 09/24/20
12.64 -74.05%
on 07/23/20
-8.97 (-73.22%)
since 07/22/20
52-Week
2.34 +40.17%
on 09/24/20
13.71 -76.08%
on 07/07/20
-0.98 (-23.00%)
since 10/22/19

Most Recent Stories

More News
Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

, /PRNewswire/ --  (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNOVATE Phase 3 program, which demonstrated the efficacy and cardiovascular safety of vadadustat...

AKBA : 3.28 (-0.46%)
Akebia Therapeut Set to Possibly Pullback After Yesterday's Rally of 1.13%

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $3.36 to a high of $3.66. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

AKBA : 3.28 (-0.46%)
Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

AKBA : 3.28 (-0.46%)
CTLT : 93.40 (+1.07%)
Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, ALRN, RIOT, PLUG, and TBIO.

ALRN : 2.11 (+4.20%)
AKBA : 3.28 (-0.46%)
RIOT : 4.05 (+1.88%)
Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined

, /PRNewswire/ --  (Nasdaq: AKBA) today announced that it will present data from its global Phase 3 programs of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients...

AKBA : 3.28 (-0.46%)
Do Options Traders Know Something About Akebia (AKBA) Stock We Don't?

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

AKBA : 3.28 (-0.46%)
Akebia Therapeut Set to Possibly Pullback After Yesterday's Rally of 2.78%

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $2.68 to a high of $2.81. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of...

AKBA : 3.28 (-0.46%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ --  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 11 newly-hired employees options to purchase an aggregate...

AKBA : 3.28 (-0.46%)
Watch for Akebia Therapeut to Potentially Rebound After Falling 5.67% Yesterday

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $2.64 to a high of $2.83. Yesterday, the shares fell 5.7%, which took the trading range below the 3-day low of $2.66...

AKBA : 3.28 (-0.46%)
Watch for Akebia Therapeut to Potentially Pullback After Gaining 9.18% Yesterday

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $2.62 to a high of $3.08. Yesterday, the shares gained 9.2%, which took the trading range above the 3-day high of...

AKBA : 3.28 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 3.67
1st Resistance Point 3.47
Last Price 3.28
1st Support Level 2.99
2nd Support Level 2.71

See More

52-Week High 13.71
Fibonacci 61.8% 9.37
Fibonacci 50% 8.02
Fibonacci 38.2% 6.68
Last Price 3.28
52-Week Low 2.34

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar